epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
Apitegromab
apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
atacicept
Atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atoncy
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
avasopasem
Avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
Awiqli (insulin icodec-abae)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Isturisa

osilodrostat

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Adult Dosing .

Dosage forms:  TAB: 1 mg, 5 mg

Cushing syndrome

[2-7 mg PO bid]
Start: 2 mg PO bid, then may incr. dose by 2-4 mg/day no more frequently than q2wk; Max: 60 mg/day; Info: for patients ineligible for or who have failed surgery; adjust dose based on tx response and urinary free cortisol levels; in patients with elevated cortisol levels receiving 10 mg bid, may further incr. dose by 10 mg/day no more frequently than q2wk

renal dosing

[see below]
renal impairment: no adjustment; Info: reduced urine free cortisol excretion if moderate-severe renal impairment; adjust dose based on urine free cortisol levels
HD/PD: not defined

hepatic dosing

[see below]
Child-Pugh Class B: start 1 mg bid; Child-Pugh Class C: start 1 mg qhs

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@47341da1
  • hypersensitivity to drug or ingredient
  • electrolyte abnormalities, uncorrected
  • avoid: breastfeeding during tx and x1wk after D/C
  • caution: renal impairment, moderate-severe
  • caution: hepatic impairment
  • caution: QT prolongation
  • caution: QT prolongation family history
  • caution: long QT syndrome, congenital
  • caution: torsades de pointes history
  • caution: ventricular arrhythmia
  • caution: bradycardia
  • caution: MI, recent
  • caution: CHF
  • caution: hypocortisolism risk

Drug Interactions .

Overview

osilodrostat

cortisol synthesis inhibitor

Interaction Characteristics:
  • CYP2B6 substrate
  • CYP3A4 substrate
  • CYP1A2 inhibitor, moderate
  • CYP2C19 inhibitor, weak
  • CYP2D6 inhibitor, weak
  • CYP3A4 inhibitor, weak
  • hypertensive effects
  • hypokalemia
  • prolongs QT interval (conditional)

Contraindicated

  • fezolinetant
  • Isturisa (osilodrostat)
    +
    fezolinetant
    1 interaction

    Contraindicated

    osilodrostat + fezolinetant

    contraindicated: combo may incr. fezolinetant levels, risk of adverse effects (hepatic metabolism inhibited)

  • pimozide
  • Isturisa (osilodrostat)
    +
    pimozide
    1 interaction

    Contraindicated

    osilodrostat + pimozide

    contraindicated: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • thioridazine
  • Isturisa (osilodrostat)
    +
    thioridazine
    1 interaction

    Contraindicated

    osilodrostat + thioridazine

    contraindicated: combo may incr. thioridazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

Avoid/Use Alternative

  • alosetron
  • Isturisa (osilodrostat)
    +
    alosetron
    1 interaction

    Avoid/Use Alternative

    osilodrostat + alosetron

    use alternative: combo may incr. alosetron levels, risk of adverse effects (hepatic metabolism inhibited)

  • alprazolam
  • Isturisa (osilodrostat)
    +
    alprazolam
    1 interaction

    Avoid/Use Alternative

    osilodrostat + alprazolam

    use alternative or monitor respiratory rate; consider decr. alprazolam dose: combo may incr. alprazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • arsenic trioxide
  • Isturisa (osilodrostat)
    +
    arsenic trioxide
    1 interaction

    Avoid/Use Alternative

    osilodrostat + arsenic trioxide

    use alternative or monitor ECG, potassium: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

  • bedaquiline
  • Isturisa (osilodrostat)
    +
    bedaquiline
    1 interaction

    Avoid/Use Alternative

    osilodrostat + bedaquiline

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • bendamustine
  • Isturisa (osilodrostat)
    +
    bendamustine
    1 interaction

    Avoid/Use Alternative

    osilodrostat + bendamustine

    consider alternatives: combo may incr. bendamustine levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • codeine
  • Isturisa (osilodrostat)
    +
    codeine
    1 interaction

    Avoid/Use Alternative

    osilodrostat + codeine

    use alternative or monitor respiratory rate, withdrawal sx: combo may incr. codeine, alter active metabolite morphine levels, incr. risk of CNS and respiratory depression, psychomotor impairment, other adverse effects or decr. efficacy (hepatic metabolism inhibited, may alter production of active metabolite morphine)

  • colchicine
  • Isturisa (osilodrostat)
    +
    colchicine
    1 interaction

    Avoid/Use Alternative

    osilodrostat + colchicine

    CV RISK REDUCTION: consider monitoring CK, myopathy s/sx; GOUT or FMF: use alternative or consider decr. colchicine dose during and x14 days after osilodrostat use: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metabolism inhibited)

  • crizotinib
  • Isturisa (osilodrostat)
    +
    crizotinib
    1 interaction

    Avoid/Use Alternative

    osilodrostat + crizotinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (hepatic metabolism inhibited, additive effects)

  • dihydrocodeine
  • Isturisa (osilodrostat)
    +
    dihydrocodeine
    1 interaction

    Avoid/Use Alternative

    osilodrostat + dihydrocodeine

    use alternative or monitor respiratory rate, withdrawal sx: combo may incr. dihydrocodeine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects; may decr. active metabolite dihydromorphine levels, efficacy (hepatic metabolism inhibited, decr. conversion to dihydromorphine)

  • domperidone
  • Isturisa (osilodrostat)
    +
    domperidone
    1 interaction

    Avoid/Use Alternative

    osilodrostat + domperidone

    use alternative or monitor ECG, HR, electrolytes: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • dronedarone
  • Isturisa (osilodrostat)
    +
    dronedarone
    1 interaction

    Avoid/Use Alternative

    osilodrostat + dronedarone

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • eliglustat
  • Isturisa (osilodrostat)
    +
    eliglustat
    1 interaction

    Avoid/Use Alternative

    osilodrostat + eliglustat

    CYP2D6 EM: monitor ECG; if Child-Pugh Class A, decr. eliglustat dose to 84 mg qd; CYP2D6 IM: monitor ECG; CYP2D6 PM: avoid combo: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • ephedra
  • Isturisa (osilodrostat)
    +
    ephedra
    1 interaction

    Avoid/Use Alternative

    osilodrostat + ephedra

    avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN (additive effects)

  • epinephrine inhaled
  • Isturisa (osilodrostat)
    +
    epinephrine inhaled
    1 interaction

    Avoid/Use Alternative

    osilodrostat + epinephrine inhaled

    avoid combo: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • eribulin
  • Isturisa (osilodrostat)
    +
    eribulin
    1 interaction

    Avoid/Use Alternative

    osilodrostat + eribulin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • fexinidazole
  • Isturisa (osilodrostat)
    +
    fexinidazole
    1 interaction

    Avoid/Use Alternative

    osilodrostat + fexinidazole

    if possible, do not initiate fexinidazole until 5 half-lives after osilodrostat D/C; use alternative or monitor ECG during and x7 days after fexinidazole tx: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. fexinidazole active metabolite levels, efficacy (additive effects; hepatic metabolism inhibited, decr. conversion to active metabolites)

  • fosfomycin injection
  • Isturisa (osilodrostat)
    +
    fosfomycin injection
    1 interaction

    Avoid/Use Alternative

    osilodrostat + fosfomycin injection

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

  • furosemide
  • Isturisa (osilodrostat)
    +
    furosemide
    1 interaction

    Avoid/Use Alternative

    osilodrostat + furosemide

    use alternative or monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • hydrocodone
  • Isturisa (osilodrostat)
    +
    hydrocodone
    1 interaction

    Avoid/Use Alternative

    osilodrostat + hydrocodone

    use alternative or monitor respiratory rate, ECG, consider decr. hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • hydroxychloroquine
  • Isturisa (osilodrostat)
    +
    hydroxychloroquine
    1 interaction

    Avoid/Use Alternative

    osilodrostat + hydroxychloroquine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • lefamulin
  • Isturisa (osilodrostat)
    +
    lefamulin
    1 interaction

    Avoid/Use Alternative

    osilodrostat + lefamulin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • lonafarnib
  • Isturisa (osilodrostat)
    +
    lonafarnib
    1 interaction

    Avoid/Use Alternative

    osilodrostat + lonafarnib

    use alternative or monitor HR, ECG, electrolytes; decr. osilodrostat dose by 50%: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • meperidine
  • Isturisa (osilodrostat)
    +
    meperidine
    1 interaction

    Avoid/Use Alternative

    osilodrostat + meperidine

    use alternative or monitor respiratory rate, ECG: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • methadone
  • Isturisa (osilodrostat)
    +
    methadone
    1 interaction

    Avoid/Use Alternative

    osilodrostat + methadone

    use alternative or monitor respiratory rate, ECG; consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • midodrine
  • Isturisa (osilodrostat)
    +
    midodrine
    1 interaction

    Avoid/Use Alternative

    osilodrostat + midodrine

    use alternative or monitor BP: combo may incr. risk of HTN (additive effects)

  • mobocertinib
  • Isturisa (osilodrostat)
    +
    mobocertinib
    1 interaction

    Avoid/Use Alternative

    osilodrostat + mobocertinib

    use alternative or monitor ECG, electrolytes: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • oxycodone
  • Isturisa (osilodrostat)
    +
    oxycodone
    1 interaction

    Avoid/Use Alternative

    osilodrostat + oxycodone

    use alternative or monitor respiratory rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • pirfenidone
  • Isturisa (osilodrostat)
    +
    pirfenidone
    1 interaction

    Avoid/Use Alternative

    osilodrostat + pirfenidone

    avoid combo if also combined w/ mod-strong CYP2C9, CYP2C19, CYP2D6, or CYP2E1 inhibitor; otherwise, consider alternative or decr. pirfenidone dose to 534 mg tid: combo may incr. pirfenidone levels, risk of adverse effects (hepatic metabolism inhibited)

  • pralsetinib
  • Isturisa (osilodrostat)
    +
    pralsetinib
    1 interaction

    Avoid/Use Alternative

    osilodrostat + pralsetinib

    if also combined w/ P-gp inhibitor, use alternative or monitor BP, consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd; otherwise, monitor BP, consider monitoring ECG, electrolytes: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • propafenone
  • Isturisa (osilodrostat)
    +
    propafenone
    1 interaction

    Avoid/Use Alternative

    osilodrostat + propafenone

    avoid combo: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metabolism inhibited, additive effects)

  • quizartinib
  • Isturisa (osilodrostat)
    +
    quizartinib
    1 interaction

    Avoid/Use Alternative

    osilodrostat + quizartinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • simvastatin
  • Isturisa (osilodrostat)
    +
    simvastatin
    1 interaction

    Avoid/Use Alternative

    osilodrostat + simvastatin

    use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 20 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

  • sotalol
  • Isturisa (osilodrostat)
    +
    sotalol
    1 interaction

    Avoid/Use Alternative

    osilodrostat + sotalol

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • tizanidine
  • Isturisa (osilodrostat)
    +
    tizanidine
    1 interaction

    Avoid/Use Alternative

    osilodrostat + tizanidine

    use alternative or monitor BP, HR: combo may incr. tizanidine levels, risk of hypotension (including orthostasis, syncope), bradycardia, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • toremifene
  • Isturisa (osilodrostat)
    +
    toremifene
    1 interaction

    Avoid/Use Alternative

    osilodrostat + toremifene

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • tramadol
  • Isturisa (osilodrostat)
    +
    tramadol
    1 interaction

    Avoid/Use Alternative

    osilodrostat + tramadol

    use alternative or monitor respiratory rate, ECG, withdrawal sx: combo may incr. tramadol levels, risk of CNS and respiratory depression, psychomotor impairment, seizures, serotonin syndrome, QT prolongation, cardiac arrhythmias, other adverse effects; may decr. active metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite; additive effects)

  • vandetanib
  • Isturisa (osilodrostat)
    +
    vandetanib
    1 interaction

    Avoid/Use Alternative

    osilodrostat + vandetanib

    use alternative or monitor ECG, electrolytes, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN (additive effects)

  • vorasidenib
  • Isturisa (osilodrostat)
    +
    vorasidenib
    1 interaction

    Avoid/Use Alternative

    osilodrostat + vorasidenib

    use alternative: combo may incr. vorasidenib levels, risk of adverse effects (hepatic metabolism inhibited)

  • ziprasidone
  • Isturisa (osilodrostat)
    +
    ziprasidone
    1 interaction

    Avoid/Use Alternative

    osilodrostat + ziprasidone

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Monitor/Modify Tx

  • abemaciclib
  • Isturisa (osilodrostat)
    +
    abemaciclib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + abemaciclib

    monitor CBC: combo may incr. abemaciclib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • abiraterone acetate
  • Isturisa (osilodrostat)
    +
    abiraterone acetate
    1 interaction

    Monitor/Modify Tx

    osilodrostat + abiraterone acetate

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • acalabrutinib
  • Isturisa (osilodrostat)
    +
    acalabrutinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + acalabrutinib

    monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • acebutolol
  • Isturisa (osilodrostat)
    +
    acebutolol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + acebutolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • acetazolamide
  • Isturisa (osilodrostat)
    +
    acetazolamide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + acetazolamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • adagrasib
  • Isturisa (osilodrostat)
    +
    adagrasib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + adagrasib

    monitor ECG, electrolytes; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • albuterol
  • Isturisa (osilodrostat)
    +
    albuterol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + albuterol

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • albuterol inhaled
  • Isturisa (osilodrostat)
    +
    albuterol inhaled
    1 interaction

    Monitor/Modify Tx

    osilodrostat + albuterol inhaled

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • aliskiren
  • Isturisa (osilodrostat)
    +
    aliskiren
    1 interaction

    Monitor/Modify Tx

    osilodrostat + aliskiren

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • almotriptan
  • Isturisa (osilodrostat)
    +
    almotriptan
    1 interaction

    Monitor/Modify Tx

    osilodrostat + almotriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • aloe
  • Isturisa (osilodrostat)
    +
    aloe
    1 interaction

    Monitor/Modify Tx

    osilodrostat + aloe

    monitor potassium w/ aloe laxative doses: combo may incr. risk of hypokalemia (additive effects)

  • amiloride
  • Isturisa (osilodrostat)
    +
    amiloride
    1 interaction

    Monitor/Modify Tx

    osilodrostat + amiloride

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • aminophylline
  • Isturisa (osilodrostat)
    +
    aminophylline
    1 interaction

    Monitor/Modify Tx

    osilodrostat + aminophylline

    monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metabolism inhibited; aminophylline converted to theophylline)

  • amiodarone
  • Isturisa (osilodrostat)
    +
    amiodarone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + amiodarone

    monitor ECG: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • amlodipine
  • Isturisa (osilodrostat)
    +
    amlodipine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + amlodipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • amphetamine
  • Isturisa (osilodrostat)
    +
    amphetamine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + amphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • amphotericin
  • Isturisa (osilodrostat)
    +
    amphotericin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + amphotericin

    monitor potassium, ECG: combo may incr. risk of hypokalemia, cardiac arrhythmias (additive effects)

  • anagrelide
  • Isturisa (osilodrostat)
    +
    anagrelide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + anagrelide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • angiotensin II
  • Isturisa (osilodrostat)
    +
    angiotensin II
    1 interaction

    Monitor/Modify Tx

    osilodrostat + angiotensin II

    monitor BP: combo may incr. risk of HTN (additive effects)

  • apalutamide
  • Isturisa (osilodrostat)
    +
    apalutamide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + apalutamide

    monitor cortisol levels, ECG: combo may decr. osilodrostat levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

  • apomorphine
  • Isturisa (osilodrostat)
    +
    apomorphine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + apomorphine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • aprocitentan
  • Isturisa (osilodrostat)
    +
    aprocitentan
    1 interaction

    Monitor/Modify Tx

    osilodrostat + aprocitentan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • arformoterol inhaled
  • Isturisa (osilodrostat)
    +
    arformoterol inhaled
    1 interaction

    Monitor/Modify Tx

    osilodrostat + arformoterol inhaled

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • armodafinil
  • Isturisa (osilodrostat)
    +
    armodafinil
    1 interaction

    Monitor/Modify Tx

    osilodrostat + armodafinil

    monitor BP: combo may incr. risk of HTN (additive effects)

  • artemether/lumefantrine
  • Isturisa (osilodrostat)
    +
    artemether/ lumefantrine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + artemether/ lumefantrine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • asciminib
  • Isturisa (osilodrostat)
    +
    asciminib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + asciminib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • asenapine
  • Isturisa (osilodrostat)
    +
    asenapine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + asenapine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • asparaginase
  • Isturisa (osilodrostat)
    +
    asparaginase
    1 interaction

    Monitor/Modify Tx

    osilodrostat + asparaginase

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • atazanavir
  • Isturisa (osilodrostat)
    +
    atazanavir
    1 interaction

    Monitor/Modify Tx

    osilodrostat + atazanavir

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • atenolol
  • Isturisa (osilodrostat)
    +
    atenolol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + atenolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • atogepant
  • Isturisa (osilodrostat)
    +
    atogepant
    1 interaction

    Monitor/Modify Tx

    osilodrostat + atogepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • atomoxetine
  • Isturisa (osilodrostat)
    +
    atomoxetine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + atomoxetine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • atropine ophthalmic
  • Isturisa (osilodrostat)
    +
    atropine ophthalmic
    1 interaction

    Monitor/Modify Tx

    osilodrostat + atropine ophthalmic

    monitor BP: combo may incr. risk of HTN (additive effects)

  • avanafil
  • Isturisa (osilodrostat)
    +
    avanafil
    1 interaction

    Monitor/Modify Tx

    osilodrostat + avanafil

    monitor BP; consider decr. avanafil dose: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

  • avapritinib
  • Isturisa (osilodrostat)
    +
    avapritinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + avapritinib

    monitor bleeding s/sx: combo may incr. avapritinib levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

  • axitinib
  • Isturisa (osilodrostat)
    +
    axitinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + axitinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • azilsartan medoxomil
  • Isturisa (osilodrostat)
    +
    azilsartan medoxomil
    1 interaction

    Monitor/Modify Tx

    osilodrostat + azilsartan medoxomil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • azithromycin
  • Isturisa (osilodrostat)
    +
    azithromycin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + azithromycin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • baxdrostat
  • Isturisa (osilodrostat)
    +
    baxdrostat
    1 interaction

    Monitor/Modify Tx

    osilodrostat + baxdrostat

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • benazepril
  • Isturisa (osilodrostat)
    +
    benazepril
    1 interaction

    Monitor/Modify Tx

    osilodrostat + benazepril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • benzphetamine
  • Isturisa (osilodrostat)
    +
    benzphetamine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + benzphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • betamethasone
  • Isturisa (osilodrostat)
    +
    betamethasone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + betamethasone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

  • betaxolol
  • Isturisa (osilodrostat)
    +
    betaxolol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + betaxolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • bevacizumab
  • Isturisa (osilodrostat)
    +
    bevacizumab
    1 interaction

    Monitor/Modify Tx

    osilodrostat + bevacizumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • bismuth subsalicylate
  • Isturisa (osilodrostat)
    +
    bismuth subsalicylate
    1 interaction

    Monitor/Modify Tx

    osilodrostat + bismuth subsalicylate

    monitor BP w/ high-dose bismuth subsalicylate: combo may incr. risk of HTN (additive effects)

  • bisoprolol
  • Isturisa (osilodrostat)
    +
    bisoprolol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + bisoprolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • brigatinib
  • Isturisa (osilodrostat)
    +
    brigatinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + brigatinib

    monitor BP, HR: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • budesonide
  • Isturisa (osilodrostat)
    +
    budesonide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + budesonide

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • bumetanide
  • Isturisa (osilodrostat)
    +
    bumetanide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + bumetanide

    monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • bupropion
  • Isturisa (osilodrostat)
    +
    bupropion
    1 interaction

    Monitor/Modify Tx

    osilodrostat + bupropion

    monitor BP: combo may incr. risk of HTN (additive effects)

  • butalbital
  • Isturisa (osilodrostat)
    +
    butalbital
    1 interaction

    Monitor/Modify Tx

    osilodrostat + butalbital

    monitor cortisol levels: combo may decr. osilodrostat levels, efficacy (hepatic metabolism induced)

  • cabozantinib
  • Isturisa (osilodrostat)
    +
    cabozantinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + cabozantinib

    monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN (additive effects)

  • caffeine
  • Isturisa (osilodrostat)
    +
    caffeine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + caffeine

    monitor BP; avoid excessive caffeine intake: combo may incr. caffeine levels, risk of HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • caffeine citrate
  • Isturisa (osilodrostat)
    +
    caffeine citrate
    1 interaction

    Monitor/Modify Tx

    osilodrostat + caffeine citrate

    monitor caffeine levels, BP: combo may incr. caffeine levels, risk of HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • candesartan cilexetil
  • Isturisa (osilodrostat)
    +
    candesartan cilexetil
    1 interaction

    Monitor/Modify Tx

    osilodrostat + candesartan cilexetil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • cannabis
  • Isturisa (osilodrostat)
    +
    cannabis
    1 interaction

    Monitor/Modify Tx

    osilodrostat + cannabis

    monitor BP: combo may incr. risk of HTN (additive effects)

  • capivasertib
  • Isturisa (osilodrostat)
    +
    capivasertib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + capivasertib

    monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

  • captopril
  • Isturisa (osilodrostat)
    +
    captopril
    1 interaction

    Monitor/Modify Tx

    osilodrostat + captopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • carbamazepine
  • Isturisa (osilodrostat)
    +
    carbamazepine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + carbamazepine

    monitor carbamazepine levels, cortisol levels: combo may incr. carbamazepine levels, adverse effects; may decr. osilodrostat levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

  • carfilzomib
  • Isturisa (osilodrostat)
    +
    carfilzomib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + carfilzomib

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • carvedilol
  • Isturisa (osilodrostat)
    +
    carvedilol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + carvedilol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • celecoxib
  • Isturisa (osilodrostat)
    +
    celecoxib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + celecoxib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ceritinib
  • Isturisa (osilodrostat)
    +
    ceritinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ceritinib

    monitor ECG, electrolytes; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • cetuximab
  • Isturisa (osilodrostat)
    +
    cetuximab
    1 interaction

    Monitor/Modify Tx

    osilodrostat + cetuximab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • chloramphenicol
  • Isturisa (osilodrostat)
    +
    chloramphenicol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + chloramphenicol

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • chloroquine
  • Isturisa (osilodrostat)
    +
    chloroquine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + chloroquine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • chlorothiazide
  • Isturisa (osilodrostat)
    +
    chlorothiazide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + chlorothiazide

    monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • chlorthalidone
  • Isturisa (osilodrostat)
    +
    chlorthalidone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + chlorthalidone

    monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • cisplatin
  • Isturisa (osilodrostat)
    +
    cisplatin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + cisplatin

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • citalopram
  • Isturisa (osilodrostat)
    +
    citalopram
    1 interaction

    Monitor/Modify Tx

    osilodrostat + citalopram

    monitor ECG; adjust max citalopram dose to 20 mg/day: combo may incr. citalopram levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • clarithromycin
  • Isturisa (osilodrostat)
    +
    clarithromycin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + clarithromycin

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • clevidipine
  • Isturisa (osilodrostat)
    +
    clevidipine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + clevidipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • clobazam
  • Isturisa (osilodrostat)
    +
    clobazam
    1 interaction

    Monitor/Modify Tx

    osilodrostat + clobazam

    monitor respiratory rate: combo may incr. clobazam and active metabolite levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • clofazimine
  • Isturisa (osilodrostat)
    +
    clofazimine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + clofazimine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • clonidine
  • Isturisa (osilodrostat)
    +
    clonidine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + clonidine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • clozapine
  • Isturisa (osilodrostat)
    +
    clozapine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + clozapine

    monitor ECG, BP, HR; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, other adverse effects (hepatic metabolism inhibited)

  • cobicistat
  • Isturisa (osilodrostat)
    +
    cobicistat
    1 interaction

    Monitor/Modify Tx

    osilodrostat + cobicistat

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • cocaine
  • Isturisa (osilodrostat)
    +
    cocaine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + cocaine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • copanlisib
  • Isturisa (osilodrostat)
    +
    copanlisib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + copanlisib

    monitor BP: combo may incr. risk of HTN (additive effects, copanlisib may cause infusion-related HTN)

  • corticotropin
  • Isturisa (osilodrostat)
    +
    corticotropin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + corticotropin

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • cortisone
  • Isturisa (osilodrostat)
    +
    cortisone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + cortisone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • cyclosporine
  • Isturisa (osilodrostat)
    +
    cyclosporine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + cyclosporine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • danazol
  • Isturisa (osilodrostat)
    +
    danazol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + danazol

    monitor BP: combo may incr. risk of HTN (additive effects)

  • darbepoetin alfa
  • Isturisa (osilodrostat)
    +
    darbepoetin alfa
    1 interaction

    Monitor/Modify Tx

    osilodrostat + darbepoetin alfa

    monitor BP: combo may incr. risk of HTN (additive effects)

  • decitabine
  • Isturisa (osilodrostat)
    +
    decitabine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + decitabine

    monitor potassium w/ IV decitabine use: combo may incr. risk of hypokalemia (additive effects)

  • deflazacort
  • Isturisa (osilodrostat)
    +
    deflazacort
    1 interaction

    Monitor/Modify Tx

    osilodrostat + deflazacort

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • degarelix
  • Isturisa (osilodrostat)
    +
    degarelix
    1 interaction

    Monitor/Modify Tx

    osilodrostat + degarelix

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • desflurane
  • Isturisa (osilodrostat)
    +
    desflurane
    1 interaction

    Monitor/Modify Tx

    osilodrostat + desflurane

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • desipramine
  • Isturisa (osilodrostat)
    +
    desipramine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + desipramine

    monitor ECG; consider monitoring desipramine levels: combo may incr. desipramine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • desmopressin
  • Isturisa (osilodrostat)
    +
    desmopressin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + desmopressin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • desvenlafaxine
  • Isturisa (osilodrostat)
    +
    desvenlafaxine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + desvenlafaxine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dexamethasone
  • Isturisa (osilodrostat)
    +
    dexamethasone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + dexamethasone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • dexmedetomidine
  • Isturisa (osilodrostat)
    +
    dexmedetomidine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + dexmedetomidine

    monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dexmedetomidine injection
  • Isturisa (osilodrostat)
    +
    dexmedetomidine injection
    1 interaction

    Monitor/Modify Tx

    osilodrostat + dexmedetomidine injection

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dexmethylphenidate
  • Isturisa (osilodrostat)
    +
    dexmethylphenidate
    1 interaction

    Monitor/Modify Tx

    osilodrostat + dexmethylphenidate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dextroamphetamine
  • Isturisa (osilodrostat)
    +
    dextroamphetamine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + dextroamphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • diazepam
  • Isturisa (osilodrostat)
    +
    diazepam
    1 interaction

    Monitor/Modify Tx

    osilodrostat + diazepam

    monitor respiratory rate: combo may incr. diazepam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • dichlorphenamide
  • Isturisa (osilodrostat)
    +
    dichlorphenamide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + dichlorphenamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • diclofenac
  • Isturisa (osilodrostat)
    +
    diclofenac
    1 interaction

    Monitor/Modify Tx

    osilodrostat + diclofenac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • diclofenac topical
  • Isturisa (osilodrostat)
    +
    diclofenac topical
    1 interaction

    Monitor/Modify Tx

    osilodrostat + diclofenac topical

    monitor BP: combo may incr. risk of HTN (additive effects)

  • diethylpropion
  • Isturisa (osilodrostat)
    +
    diethylpropion
    1 interaction

    Monitor/Modify Tx

    osilodrostat + diethylpropion

    monitor BP: combo may incr. risk of HTN (additive effects)

  • diflunisal
  • Isturisa (osilodrostat)
    +
    diflunisal
    1 interaction

    Monitor/Modify Tx

    osilodrostat + diflunisal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • digoxin
  • Isturisa (osilodrostat)
    +
    digoxin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + digoxin

    monitor electrolytes: combo may incr. risk of digoxin toxicity, cardiac arrhythmias (electrolyte abnormalities may incr. digoxin sensitivity)

  • dihydroergotamine
  • Isturisa (osilodrostat)
    +
    dihydroergotamine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + dihydroergotamine

    monitor BP: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • diltiazem
  • Isturisa (osilodrostat)
    +
    diltiazem
    1 interaction

    Monitor/Modify Tx

    osilodrostat + diltiazem

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • dinutuximab
  • Isturisa (osilodrostat)
    +
    dinutuximab
    1 interaction

    Monitor/Modify Tx

    osilodrostat + dinutuximab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • disopyramide
  • Isturisa (osilodrostat)
    +
    disopyramide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + disopyramide

    monitor disopyramide levels, ECG: combo may incr. disopyramide levels, risk of adverse effects, risk of QT prolongation, cardiac arrhythmias (hepatic metabolism inhibited, additive effects)

  • dobutamine
  • Isturisa (osilodrostat)
    +
    dobutamine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + dobutamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • docetaxel
  • Isturisa (osilodrostat)
    +
    docetaxel
    1 interaction

    Monitor/Modify Tx

    osilodrostat + docetaxel

    monitor CBC: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • dofetilide
  • Isturisa (osilodrostat)
    +
    dofetilide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + dofetilide

    monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • donepezil
  • Isturisa (osilodrostat)
    +
    donepezil
    1 interaction

    Monitor/Modify Tx

    osilodrostat + donepezil

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dopamine
  • Isturisa (osilodrostat)
    +
    dopamine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + dopamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dordaviprone
  • Isturisa (osilodrostat)
    +
    dordaviprone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + dordaviprone

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • doxapram
  • Isturisa (osilodrostat)
    +
    doxapram
    1 interaction

    Monitor/Modify Tx

    osilodrostat + doxapram

    monitor BP: combo may incr. risk of HTN (additive effects)

  • doxazosin
  • Isturisa (osilodrostat)
    +
    doxazosin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + doxazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • dronabinol
  • Isturisa (osilodrostat)
    +
    dronabinol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + dronabinol

    monitor BP: combo may incr. risk of HTN (additive effects)

  • droperidol
  • Isturisa (osilodrostat)
    +
    droperidol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + droperidol

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • droxidopa
  • Isturisa (osilodrostat)
    +
    droxidopa
    1 interaction

    Monitor/Modify Tx

    osilodrostat + droxidopa

    monitor BP: combo may incr. risk of HTN (additive effects)

  • eletriptan
  • Isturisa (osilodrostat)
    +
    eletriptan
    1 interaction

    Monitor/Modify Tx

    osilodrostat + eletriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • emapalumab
  • Isturisa (osilodrostat)
    +
    emapalumab
    1 interaction

    Monitor/Modify Tx

    osilodrostat + emapalumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • enalapril
  • Isturisa (osilodrostat)
    +
    enalapril
    1 interaction

    Monitor/Modify Tx

    osilodrostat + enalapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • enalaprilat
  • Isturisa (osilodrostat)
    +
    enalaprilat
    1 interaction

    Monitor/Modify Tx

    osilodrostat + enalaprilat

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • encorafenib
  • Isturisa (osilodrostat)
    +
    encorafenib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + encorafenib

    monitor ECG, electrolytes, cortisol levels: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. osilodrostat levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

  • ensitrelvir
  • Isturisa (osilodrostat)
    +
    ensitrelvir
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ensitrelvir

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • entrectinib
  • Isturisa (osilodrostat)
    +
    entrectinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + entrectinib

    monitor ECG: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • enzalutamide
  • Isturisa (osilodrostat)
    +
    enzalutamide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + enzalutamide

    monitor cortisol levels: combo may decr. osilodrostat levels, efficacy (hepatic metabolism induced)

  • ephedrine injection
  • Isturisa (osilodrostat)
    +
    ephedrine injection
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ephedrine injection

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ephedrine oral
  • Isturisa (osilodrostat)
    +
    ephedrine oral
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ephedrine oral

    monitor BP: combo may incr. risk of HTN (additive effects)

  • epinephrine
  • Isturisa (osilodrostat)
    +
    epinephrine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + epinephrine

    monitor BP, potassium, ECG: combo may incr. risk of HTN, hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • epirubicin
  • Isturisa (osilodrostat)
    +
    epirubicin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + epirubicin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • eplerenone
  • Isturisa (osilodrostat)
    +
    eplerenone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + eplerenone

    monitor potassium, BP: combo may incr. eplerenone levels, risk of hyperkalemia, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • epoetin alfa
  • Isturisa (osilodrostat)
    +
    epoetin alfa
    1 interaction

    Monitor/Modify Tx

    osilodrostat + epoetin alfa

    monitor BP: combo may incr. risk of HTN (additive effects)

  • eptinezumab
  • Isturisa (osilodrostat)
    +
    eptinezumab
    1 interaction

    Monitor/Modify Tx

    osilodrostat + eptinezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • erenumab
  • Isturisa (osilodrostat)
    +
    erenumab
    1 interaction

    Monitor/Modify Tx

    osilodrostat + erenumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ergotamine
  • Isturisa (osilodrostat)
    +
    ergotamine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ergotamine

    monitor BP: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • erythromycin
  • Isturisa (osilodrostat)
    +
    erythromycin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + erythromycin

    monitor ECG: combo may incr. erythromycin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effect (hepatic metabolism inhibited, additive effects)

  • esketamine
  • Isturisa (osilodrostat)
    +
    esketamine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + esketamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • esmolol
  • Isturisa (osilodrostat)
    +
    esmolol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + esmolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • estetrol (contraceptive)
  • Isturisa (osilodrostat)
    +
    estetrol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    osilodrostat + estetrol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • estradiol (contraceptive)
  • Isturisa (osilodrostat)
    +
    estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    osilodrostat + estradiol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ethacrynic acid
  • Isturisa (osilodrostat)
    +
    ethacrynic acid
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ethacrynic acid

    monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • ethanol (alcoholic beverage)
  • Isturisa (osilodrostat)
    +
    ethanol (alcoholic beverage)
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ethanol (alcoholic beverage)

    monitor BP: combo may incr. risk of HTN (chronic alcohol use) (additive effects)

  • ethinyl estradiol (contraceptive)
  • Isturisa (osilodrostat)
    +
    ethinyl estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ethinyl estradiol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • etodolac
  • Isturisa (osilodrostat)
    +
    etodolac
    1 interaction

    Monitor/Modify Tx

    osilodrostat + etodolac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • etrasimod
  • Isturisa (osilodrostat)
    +
    etrasimod
    1 interaction

    Monitor/Modify Tx

    osilodrostat + etrasimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • everolimus
  • Isturisa (osilodrostat)
    +
    everolimus
    1 interaction

    Monitor/Modify Tx

    osilodrostat + everolimus

    TSC-ASSOCIATED SEGA, TSC-ASSOCIATED PARTIAL-ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC; OTHER INDICATIONS: monitor CBC: combo may incr. everolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • fedratinib
  • Isturisa (osilodrostat)
    +
    fedratinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + fedratinib

    monitor CBC, LFTs: combo may incr. fedratinib levels, risk of myelosuppression, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

  • felodipine
  • Isturisa (osilodrostat)
    +
    felodipine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + felodipine

    monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • fenfluramine
  • Isturisa (osilodrostat)
    +
    fenfluramine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + fenfluramine

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • fenoldopam
  • Isturisa (osilodrostat)
    +
    fenoldopam
    1 interaction

    Monitor/Modify Tx

    osilodrostat + fenoldopam

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fenoprofen
  • Isturisa (osilodrostat)
    +
    fenoprofen
    1 interaction

    Monitor/Modify Tx

    osilodrostat + fenoprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fentanyl
  • Isturisa (osilodrostat)
    +
    fentanyl
    1 interaction

    Monitor/Modify Tx

    osilodrostat + fentanyl

    monitor respiratory rate, consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • finerenone
  • Isturisa (osilodrostat)
    +
    finerenone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + finerenone

    monitor potassium: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

  • fingolimod
  • Isturisa (osilodrostat)
    +
    fingolimod
    1 interaction

    Monitor/Modify Tx

    osilodrostat + fingolimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • flecainide
  • Isturisa (osilodrostat)
    +
    flecainide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + flecainide

    monitor flecainide levels, ECG: combo may incr. flecainide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • flibanserin
  • Isturisa (osilodrostat)
    +
    flibanserin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + flibanserin

    monitor BP: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (including syncope), other adverse effects (hepatic metabolism inhibited)

  • fludrocortisone
  • Isturisa (osilodrostat)
    +
    fludrocortisone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + fludrocortisone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • fluorouracil
  • Isturisa (osilodrostat)
    +
    fluorouracil
    1 interaction

    Monitor/Modify Tx

    osilodrostat + fluorouracil

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • flurbiprofen
  • Isturisa (osilodrostat)
    +
    flurbiprofen
    1 interaction

    Monitor/Modify Tx

    osilodrostat + flurbiprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • formoterol inhaled
  • Isturisa (osilodrostat)
    +
    formoterol inhaled
    1 interaction

    Monitor/Modify Tx

    osilodrostat + formoterol inhaled

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • foscarnet
  • Isturisa (osilodrostat)
    +
    foscarnet
    1 interaction

    Monitor/Modify Tx

    osilodrostat + foscarnet

    monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • fosinopril
  • Isturisa (osilodrostat)
    +
    fosinopril
    1 interaction

    Monitor/Modify Tx

    osilodrostat + fosinopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fosphenytoin
  • Isturisa (osilodrostat)
    +
    fosphenytoin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + fosphenytoin

    monitor phenytoin, cortisol levels: combo may incr. phenytoin levels, risk of toxicity; may decr. osilodrostat levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

  • fostamatinib
  • Isturisa (osilodrostat)
    +
    fostamatinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + fostamatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fremanezumab
  • Isturisa (osilodrostat)
    +
    fremanezumab
    1 interaction

    Monitor/Modify Tx

    osilodrostat + fremanezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • frovatriptan
  • Isturisa (osilodrostat)
    +
    frovatriptan
    1 interaction

    Monitor/Modify Tx

    osilodrostat + frovatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fruquintinib
  • Isturisa (osilodrostat)
    +
    fruquintinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + fruquintinib

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • galcanezumab
  • Isturisa (osilodrostat)
    +
    galcanezumab
    1 interaction

    Monitor/Modify Tx

    osilodrostat + galcanezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • gepirone
  • Isturisa (osilodrostat)
    +
    gepirone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + gepirone

    monitor ECG, electrolytes: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • gilteritinib
  • Isturisa (osilodrostat)
    +
    gilteritinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + gilteritinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • glasdegib
  • Isturisa (osilodrostat)
    +
    glasdegib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + glasdegib

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • goserelin
  • Isturisa (osilodrostat)
    +
    goserelin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + goserelin

    PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • guanfacine
  • Isturisa (osilodrostat)
    +
    guanfacine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + guanfacine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • haloperidol
  • Isturisa (osilodrostat)
    +
    haloperidol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + haloperidol

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • histrelin
  • Isturisa (osilodrostat)
    +
    histrelin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + histrelin

    consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • hoodia
  • Isturisa (osilodrostat)
    +
    hoodia
    1 interaction

    Monitor/Modify Tx

    osilodrostat + hoodia

    monitor BP: combo may incr. risk of HTN (additive effects)

  • hydralazine
  • Isturisa (osilodrostat)
    +
    hydralazine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + hydralazine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • hydrochlorothiazide
  • Isturisa (osilodrostat)
    +
    hydrochlorothiazide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + hydrochlorothiazide

    monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • hydrocortisone
  • Isturisa (osilodrostat)
    +
    hydrocortisone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + hydrocortisone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • hydroxocobalamin IV
  • Isturisa (osilodrostat)
    +
    hydroxocobalamin IV
    1 interaction

    Monitor/Modify Tx

    osilodrostat + hydroxocobalamin IV

    monitor BP: combo may incr. risk of HTN (additive effects)

  • hydroxyzine
  • Isturisa (osilodrostat)
    +
    hydroxyzine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + hydroxyzine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ibrutinib
  • Isturisa (osilodrostat)
    +
    ibrutinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ibrutinib

    monitor BP; consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ibuprofen
  • Isturisa (osilodrostat)
    +
    ibuprofen
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ibuprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ibutilide
  • Isturisa (osilodrostat)
    +
    ibutilide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ibutilide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • idelalisib
  • Isturisa (osilodrostat)
    +
    idelalisib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + idelalisib

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • imipramine
  • Isturisa (osilodrostat)
    +
    imipramine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + imipramine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • indapamide
  • Isturisa (osilodrostat)
    +
    indapamide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + indapamide

    monitor BP, potassium: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • indomethacin
  • Isturisa (osilodrostat)
    +
    indomethacin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + indomethacin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • inotuzumab ozogamicin
  • Isturisa (osilodrostat)
    +
    inotuzumab ozogamicin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + inotuzumab ozogamicin

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • insulin
  • Isturisa (osilodrostat)
    +
    insulin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + insulin

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • irbesartan
  • Isturisa (osilodrostat)
    +
    irbesartan
    1 interaction

    Monitor/Modify Tx

    osilodrostat + irbesartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • isoflurane
  • Isturisa (osilodrostat)
    +
    isoflurane
    1 interaction

    Monitor/Modify Tx

    osilodrostat + isoflurane

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • isoproterenol
  • Isturisa (osilodrostat)
    +
    isoproterenol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + isoproterenol

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • isradipine
  • Isturisa (osilodrostat)
    +
    isradipine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + isradipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • itraconazole
  • Isturisa (osilodrostat)
    +
    itraconazole
    1 interaction

    Monitor/Modify Tx

    osilodrostat + itraconazole

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • ivabradine
  • Isturisa (osilodrostat)
    +
    ivabradine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ivabradine

    monitor HR, ECG: combo may incr. ivabradine levels, risk of bradycardia, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • ivosidenib
  • Isturisa (osilodrostat)
    +
    ivosidenib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ivosidenib

    monitor ECG, electrolytes, cortisol levels: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. osilodrostat levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

  • ixabepilone
  • Isturisa (osilodrostat)
    +
    ixabepilone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ixabepilone

    monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • ketamine
  • Isturisa (osilodrostat)
    +
    ketamine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ketamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ketoconazole
  • Isturisa (osilodrostat)
    +
    ketoconazole
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ketoconazole

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • ketoprofen
  • Isturisa (osilodrostat)
    +
    ketoprofen
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ketoprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ketorolac
  • Isturisa (osilodrostat)
    +
    ketorolac
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ketorolac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • labetalol
  • Isturisa (osilodrostat)
    +
    labetalol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + labetalol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lanreotide
  • Isturisa (osilodrostat)
    +
    lanreotide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + lanreotide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • leflunomide
  • Isturisa (osilodrostat)
    +
    leflunomide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + leflunomide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • lemborexant
  • Isturisa (osilodrostat)
    +
    lemborexant
    1 interaction

    Monitor/Modify Tx

    osilodrostat + lemborexant

    adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • lenalidomide
  • Isturisa (osilodrostat)
    +
    lenalidomide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + lenalidomide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • lenvatinib
  • Isturisa (osilodrostat)
    +
    lenvatinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + lenvatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • leuprolide
  • Isturisa (osilodrostat)
    +
    leuprolide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + leuprolide

    PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • levalbuterol inhaled
  • Isturisa (osilodrostat)
    +
    levalbuterol inhaled
    1 interaction

    Monitor/Modify Tx

    osilodrostat + levalbuterol inhaled

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • levofloxacin
  • Isturisa (osilodrostat)
    +
    levofloxacin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + levofloxacin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • levoketoconazole
  • Isturisa (osilodrostat)
    +
    levoketoconazole
    1 interaction

    Monitor/Modify Tx

    osilodrostat + levoketoconazole

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • levomilnacipran
  • Isturisa (osilodrostat)
    +
    levomilnacipran
    1 interaction

    Monitor/Modify Tx

    osilodrostat + levomilnacipran

    monitor BP: combo may incr. risk of HTN (additive effects)

  • licorice
  • Isturisa (osilodrostat)
    +
    licorice
    1 interaction

    Monitor/Modify Tx

    osilodrostat + licorice

    monitor BP, potassium w/ large amounts of licorice: combo may incr. risk of HTN, hypokalemia (additive effects)

  • lidocaine
  • Isturisa (osilodrostat)
    +
    lidocaine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + lidocaine

    monitor lidocaine levels if lidocaine antiarrhythmic use; otherwise, monitor BP, HR: combo may incr. lidocaine levels, risk of hypotension, bradycardia, other adverse effects; risk may be higher with continuous infusion or higher doses for local anesthesia (hepatic metabolism inhibited)

  • lisdexamfetamine
  • Isturisa (osilodrostat)
    +
    lisdexamfetamine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + lisdexamfetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • lisinopril
  • Isturisa (osilodrostat)
    +
    lisinopril
    1 interaction

    Monitor/Modify Tx

    osilodrostat + lisinopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lofexidine
  • Isturisa (osilodrostat)
    +
    lofexidine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + lofexidine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • lomitapide
  • Isturisa (osilodrostat)
    +
    lomitapide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + lomitapide

    ADULT PATIENTS: if patient on stable osilodrostat dose and starting lomitapide, adjust max lomitapide dose to 30 mg/day; if patient on stable lomitapide dose and starting osilodrostat, decr. lomitapide dose by 50% and adjust max lomitapide dose to 30 mg/day; PEDIATRIC PATIENTS: if patient on stable osilodrostat dose and starting lomitapide, adjust max lomitapide dose to 10 mg/day if 2-10 yo or 20 mg/day if 11-17 yo; if patient on stable lomitapide dose and starting osilodrostat, decr. lomitapide dose by 50% and adjust max lomitapide dose to 10 mg/day if 2-10 yo or 20 mg/day if 11-17 yo: combo may incr. lomitapide levels, risk of hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

  • lopinavir/ritonavir
  • Isturisa (osilodrostat)
    +
    lopinavir/ ritonavir
    1 interaction

    Monitor/Modify Tx

    osilodrostat + lopinavir/ ritonavir

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • lorlatinib
  • Isturisa (osilodrostat)
    +
    lorlatinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + lorlatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • losartan
  • Isturisa (osilodrostat)
    +
    losartan
    1 interaction

    Monitor/Modify Tx

    osilodrostat + losartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lovastatin
  • Isturisa (osilodrostat)
    +
    lovastatin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + lovastatin

    monitor CK, myopathy sx: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

  • lumacaftor/ivacaftor
  • Isturisa (osilodrostat)
    +
    lumacaftor/ ivacaftor
    1 interaction

    Monitor/Modify Tx

    osilodrostat + lumacaftor/ ivacaftor

    monitor BP, cortisol levels: combo may decr. osilodrostat levels, efficacy; may incr. risk of HTN (hepatic metabolism induced; additive effects)

  • lumateperone
  • Isturisa (osilodrostat)
    +
    lumateperone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + lumateperone

    monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • lurasidone
  • Isturisa (osilodrostat)
    +
    lurasidone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + lurasidone

    monitor ECG: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • lurbinectedin
  • Isturisa (osilodrostat)
    +
    lurbinectedin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + lurbinectedin

    monitor CBC: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • luspatercept
  • Isturisa (osilodrostat)
    +
    luspatercept
    1 interaction

    Monitor/Modify Tx

    osilodrostat + luspatercept

    monitor BP: combo may incr. risk of HTN (additive effects)

  • macimorelin
  • Isturisa (osilodrostat)
    +
    macimorelin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + macimorelin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • magnesium citrate
  • Isturisa (osilodrostat)
    +
    magnesium citrate
    1 interaction

    Monitor/Modify Tx

    osilodrostat + magnesium citrate

    monitor potassium, consider monitoring ECG if magnesium citrate bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • magnesium salicylate
  • Isturisa (osilodrostat)
    +
    magnesium salicylate
    1 interaction

    Monitor/Modify Tx

    osilodrostat + magnesium salicylate

    monitor BP w/ high-dose magnesium salicylate: combo may incr. risk of HTN (additive effects)

  • mannitol
  • Isturisa (osilodrostat)
    +
    mannitol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + mannitol

    monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • mavacamten
  • Isturisa (osilodrostat)
    +
    mavacamten
    1 interaction

    Monitor/Modify Tx

    osilodrostat + mavacamten

    monitor cardiac fxn, incl. LVEF; if patient stable on osilodrostat tx, initiate mavacamten at 5 mg qd; if adding short-term (<1wk) osilodrostat tx to existing mavacamten tx, hold mavacamten until osilodrostat D/C; if adding longer-term (>1wk) osilodrostat tx, decr. mavacamten dose as follows for at least 12wk: decr. mavacamten 15 mg qd to 10 mg qd; decr. mavacamten 10 mg qd to 5 mg qd; decr. mavacamten 5 mg qd to 2.5 mg qd; do not start osilodrostat tx if on mavacamten 2.5 mg qd: combo may incr. mavacamten levels, risk of heart failure, other adverse effects (hepatic metabolism inhibited)

  • meclofenamate
  • Isturisa (osilodrostat)
    +
    meclofenamate
    1 interaction

    Monitor/Modify Tx

    osilodrostat + meclofenamate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • mefenamic acid
  • Isturisa (osilodrostat)
    +
    mefenamic acid
    1 interaction

    Monitor/Modify Tx

    osilodrostat + mefenamic acid

    monitor BP: combo may incr. risk of HTN (additive effects)

  • meloxicam
  • Isturisa (osilodrostat)
    +
    meloxicam
    1 interaction

    Monitor/Modify Tx

    osilodrostat + meloxicam

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methamphetamine
  • Isturisa (osilodrostat)
    +
    methamphetamine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + methamphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methazolamide
  • Isturisa (osilodrostat)
    +
    methazolamide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + methazolamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • methoxy polyethylene glycol-epoetin beta
  • Isturisa (osilodrostat)
    +
    methoxy polyethylene glycol-epoetin beta
    1 interaction

    Monitor/Modify Tx

    osilodrostat + methoxy polyethylene glycol-epoetin beta

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methyldopa
  • Isturisa (osilodrostat)
    +
    methyldopa
    1 interaction

    Monitor/Modify Tx

    osilodrostat + methyldopa

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • methylergonovine
  • Isturisa (osilodrostat)
    +
    methylergonovine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + methylergonovine

    monitor BP: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • methylphenidate
  • Isturisa (osilodrostat)
    +
    methylphenidate
    1 interaction

    Monitor/Modify Tx

    osilodrostat + methylphenidate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methylprednisolone
  • Isturisa (osilodrostat)
    +
    methylprednisolone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + methylprednisolone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • methyltestosterone
  • Isturisa (osilodrostat)
    +
    methyltestosterone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + methyltestosterone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • metoclopramide
  • Isturisa (osilodrostat)
    +
    metoclopramide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + metoclopramide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • metolazone
  • Isturisa (osilodrostat)
    +
    metolazone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + metolazone

    monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • metoprolol
  • Isturisa (osilodrostat)
    +
    metoprolol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + metoprolol

    monitor BP: combo may incr. metoprolol levels, risk of hypotension, bradycardia, AV block, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • midazolam
  • Isturisa (osilodrostat)
    +
    midazolam
    1 interaction

    Monitor/Modify Tx

    osilodrostat + midazolam

    monitor respiratory rate: combo may incr. midazolam and active metabolite levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • mifepristone
  • Isturisa (osilodrostat)
    +
    mifepristone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + mifepristone

    monitor ECG; decr. osilodrostat dose by 50% during and x14 days after daily mifepristone use; monitor potassium if daily mifepristone use: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, hypokalemia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • milnacipran
  • Isturisa (osilodrostat)
    +
    milnacipran
    1 interaction

    Monitor/Modify Tx

    osilodrostat + milnacipran

    monitor BP: combo may incr. risk of HTN (additive effects)

  • minoxidil
  • Isturisa (osilodrostat)
    +
    minoxidil
    1 interaction

    Monitor/Modify Tx

    osilodrostat + minoxidil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • mirabegron
  • Isturisa (osilodrostat)
    +
    mirabegron
    1 interaction

    Monitor/Modify Tx

    osilodrostat + mirabegron

    monitor BP: combo may incr. risk of HTN (additive effects)

  • mitotane
  • Isturisa (osilodrostat)
    +
    mitotane
    1 interaction

    Monitor/Modify Tx

    osilodrostat + mitotane

    monitor cortisol levels: combo may decr. osilodrostat levels, efficacy (hepatic metabolism induced)

  • modafinil
  • Isturisa (osilodrostat)
    +
    modafinil
    1 interaction

    Monitor/Modify Tx

    osilodrostat + modafinil

    monitor BP: combo may incr. risk of HTN (additive effects)

  • moexipril
  • Isturisa (osilodrostat)
    +
    moexipril
    1 interaction

    Monitor/Modify Tx

    osilodrostat + moexipril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • motixafortide
  • Isturisa (osilodrostat)
    +
    motixafortide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + motixafortide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • moxifloxacin
  • Isturisa (osilodrostat)
    +
    moxifloxacin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + moxifloxacin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • nabumetone
  • Isturisa (osilodrostat)
    +
    nabumetone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + nabumetone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nadolol
  • Isturisa (osilodrostat)
    +
    nadolol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + nadolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • naproxen
  • Isturisa (osilodrostat)
    +
    naproxen
    1 interaction

    Monitor/Modify Tx

    osilodrostat + naproxen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • naratriptan
  • Isturisa (osilodrostat)
    +
    naratriptan
    1 interaction

    Monitor/Modify Tx

    osilodrostat + naratriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • naxitamab
  • Isturisa (osilodrostat)
    +
    naxitamab
    1 interaction

    Monitor/Modify Tx

    osilodrostat + naxitamab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nebivolol
  • Isturisa (osilodrostat)
    +
    nebivolol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + nebivolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • necitumumab
  • Isturisa (osilodrostat)
    +
    necitumumab
    1 interaction

    Monitor/Modify Tx

    osilodrostat + necitumumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • nefazodone
  • Isturisa (osilodrostat)
    +
    nefazodone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + nefazodone

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • nelfinavir
  • Isturisa (osilodrostat)
    +
    nelfinavir
    1 interaction

    Monitor/Modify Tx

    osilodrostat + nelfinavir

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • nicardipine
  • Isturisa (osilodrostat)
    +
    nicardipine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + nicardipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nicotine
  • Isturisa (osilodrostat)
    +
    nicotine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + nicotine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nifedipine
  • Isturisa (osilodrostat)
    +
    nifedipine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + nifedipine

    monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • nilotinib
  • Isturisa (osilodrostat)
    +
    nilotinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + nilotinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (hepatic metabolism inhibited, additive effects)

  • nimodipine
  • Isturisa (osilodrostat)
    +
    nimodipine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + nimodipine

    monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects; may decr. nimodipine efficacy (hepatic metabolism inhibited; antagonistic effects)

  • niraparib
  • Isturisa (osilodrostat)
    +
    niraparib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + niraparib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nisoldipine
  • Isturisa (osilodrostat)
    +
    nisoldipine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + nisoldipine

    monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • norepinephrine
  • Isturisa (osilodrostat)
    +
    norepinephrine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + norepinephrine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nortriptyline
  • Isturisa (osilodrostat)
    +
    nortriptyline
    1 interaction

    Monitor/Modify Tx

    osilodrostat + nortriptyline

    consider monitoring nortriptyline levels: combo may incr. nortriptyline levels, risk of adverse effects (hepatic metabolism inhibited)

  • obinutuzumab
  • Isturisa (osilodrostat)
    +
    obinutuzumab
    1 interaction

    Monitor/Modify Tx

    osilodrostat + obinutuzumab

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • oliceridine
  • Isturisa (osilodrostat)
    +
    oliceridine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + oliceridine

    monitor respiratory rate, ECG: combo may incr. oliceridine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • olmesartan medoxomil
  • Isturisa (osilodrostat)
    +
    olmesartan medoxomil
    1 interaction

    Monitor/Modify Tx

    osilodrostat + olmesartan medoxomil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • olodaterol inhaled
  • Isturisa (osilodrostat)
    +
    olodaterol inhaled
    1 interaction

    Monitor/Modify Tx

    osilodrostat + olodaterol inhaled

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • ondansetron
  • Isturisa (osilodrostat)
    +
    ondansetron
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ondansetron

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • osimertinib
  • Isturisa (osilodrostat)
    +
    osimertinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + osimertinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • oxaprozin
  • Isturisa (osilodrostat)
    +
    oxaprozin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + oxaprozin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • oxymetazoline nasal
  • Isturisa (osilodrostat)
    +
    oxymetazoline nasal
    1 interaction

    Monitor/Modify Tx

    osilodrostat + oxymetazoline nasal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • oxytocin
  • Isturisa (osilodrostat)
    +
    oxytocin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + oxytocin

    monitor BP: combo may incr. risk of HTN, including life-threatening (additive effects)

  • ozanimod
  • Isturisa (osilodrostat)
    +
    ozanimod
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ozanimod

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • pacritinib
  • Isturisa (osilodrostat)
    +
    pacritinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + pacritinib

    monitor ECG, electrolytes, CBC, bleeding s/sx: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

  • paliperidone
  • Isturisa (osilodrostat)
    +
    paliperidone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + paliperidone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • palonosetron
  • Isturisa (osilodrostat)
    +
    palonosetron
    1 interaction

    Monitor/Modify Tx

    osilodrostat + palonosetron

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pamidronate
  • Isturisa (osilodrostat)
    +
    pamidronate
    1 interaction

    Monitor/Modify Tx

    osilodrostat + pamidronate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • panitumumab
  • Isturisa (osilodrostat)
    +
    panitumumab
    1 interaction

    Monitor/Modify Tx

    osilodrostat + panitumumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • pasireotide
  • Isturisa (osilodrostat)
    +
    pasireotide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + pasireotide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pazopanib
  • Isturisa (osilodrostat)
    +
    pazopanib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + pazopanib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • pemigatinib
  • Isturisa (osilodrostat)
    +
    pemigatinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + pemigatinib

    monitor phosphate: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

  • pentamidine
  • Isturisa (osilodrostat)
    +
    pentamidine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + pentamidine

    monitor ECG; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pentobarbital
  • Isturisa (osilodrostat)
    +
    pentobarbital
    1 interaction

    Monitor/Modify Tx

    osilodrostat + pentobarbital

    monitor cortisol levels: combo may decr. osilodrostat levels, efficacy (hepatic metabolism induced)

  • perindopril
  • Isturisa (osilodrostat)
    +
    perindopril
    1 interaction

    Monitor/Modify Tx

    osilodrostat + perindopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • pexidartinib
  • Isturisa (osilodrostat)
    +
    pexidartinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + pexidartinib

    monitor BP: combo may incr. pexidartinib levels, risk of hepatotoxicity, HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • phendimetrazine
  • Isturisa (osilodrostat)
    +
    phendimetrazine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + phendimetrazine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenobarbital
  • Isturisa (osilodrostat)
    +
    phenobarbital
    1 interaction

    Monitor/Modify Tx

    osilodrostat + phenobarbital

    monitor cortisol levels: combo may decr. osilodrostat levels, efficacy (hepatic metabolism induced)

  • phenoxybenzamine
  • Isturisa (osilodrostat)
    +
    phenoxybenzamine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + phenoxybenzamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phentermine
  • Isturisa (osilodrostat)
    +
    phentermine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + phentermine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phentolamine
  • Isturisa (osilodrostat)
    +
    phentolamine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + phentolamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phenylephrine
  • Isturisa (osilodrostat)
    +
    phenylephrine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + phenylephrine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenylephrine injection
  • Isturisa (osilodrostat)
    +
    phenylephrine injection
    1 interaction

    Monitor/Modify Tx

    osilodrostat + phenylephrine injection

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenylephrine nasal
  • Isturisa (osilodrostat)
    +
    phenylephrine nasal
    1 interaction

    Monitor/Modify Tx

    osilodrostat + phenylephrine nasal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenylephrine ophthalmic
  • Isturisa (osilodrostat)
    +
    phenylephrine ophthalmic
    1 interaction

    Monitor/Modify Tx

    osilodrostat + phenylephrine ophthalmic

    monitor BP; HTN risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may incr. risk of HTN (additive effects)

  • phenylephrine rectal
  • Isturisa (osilodrostat)
    +
    phenylephrine rectal
    1 interaction

    Monitor/Modify Tx

    osilodrostat + phenylephrine rectal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenytoin
  • Isturisa (osilodrostat)
    +
    phenytoin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + phenytoin

    monitor phenytoin, cortisol levels: combo may incr. phenytoin levels, risk of toxicity; may decr. osilodrostat levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

  • pindolol
  • Isturisa (osilodrostat)
    +
    pindolol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + pindolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • piroxicam
  • Isturisa (osilodrostat)
    +
    piroxicam
    1 interaction

    Monitor/Modify Tx

    osilodrostat + piroxicam

    monitor BP: combo may incr. risk of HTN (additive effects)

  • polyethylene glycol
  • Isturisa (osilodrostat)
    +
    polyethylene glycol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + polyethylene glycol

    monitor potassium, consider monitoring ECG if polyethylene glycol bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • polyethylene glycol/electrolytes
  • Isturisa (osilodrostat)
    +
    polyethylene glycol/ electrolytes
    1 interaction

    Monitor/Modify Tx

    osilodrostat + polyethylene glycol/ electrolytes

    monitor potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • pomalidomide
  • Isturisa (osilodrostat)
    +
    pomalidomide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + pomalidomide

    monitor CBC: combo may incr. pomalidomide levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • ponatinib
  • Isturisa (osilodrostat)
    +
    ponatinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ponatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ponesimod
  • Isturisa (osilodrostat)
    +
    ponesimod
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ponesimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • posaconazole
  • Isturisa (osilodrostat)
    +
    posaconazole
    1 interaction

    Monitor/Modify Tx

    osilodrostat + posaconazole

    monitor ECG, potassium; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, hypokalemia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • prazosin
  • Isturisa (osilodrostat)
    +
    prazosin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + prazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • prednisolone
  • Isturisa (osilodrostat)
    +
    prednisolone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + prednisolone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • prednisone
  • Isturisa (osilodrostat)
    +
    prednisone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + prednisone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • primidone
  • Isturisa (osilodrostat)
    +
    primidone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + primidone

    monitor cortisol levels: combo may decr. osilodrostat levels, efficacy (hepatic metabolism induced)

  • procainamide
  • Isturisa (osilodrostat)
    +
    procainamide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + procainamide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • propranolol
  • Isturisa (osilodrostat)
    +
    propranolol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + propranolol

    monitor BP, HR: combo may incr. propranolol levels, risk of hypotension, bradycardia, AV block, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • protriptyline
  • Isturisa (osilodrostat)
    +
    protriptyline
    1 interaction

    Monitor/Modify Tx

    osilodrostat + protriptyline

    monitor BP: combo may incr. risk of HTN (additive effects)

  • pseudoephedrine
  • Isturisa (osilodrostat)
    +
    pseudoephedrine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + pseudoephedrine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • quetiapine
  • Isturisa (osilodrostat)
    +
    quetiapine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + quetiapine

    monitor BP, especially in pts <18 yo: combo may incr. risk of HTN (additive effects)

  • quinapril
  • Isturisa (osilodrostat)
    +
    quinapril
    1 interaction

    Monitor/Modify Tx

    osilodrostat + quinapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • quinidine (antiarrhythmic)
  • Isturisa (osilodrostat)
    +
    quinidine (antiarrhythmic)
    1 interaction

    Monitor/Modify Tx

    osilodrostat + quinidine (antiarrhythmic)

    monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • quinidine (CYP2D6 inhibitor)
  • Isturisa (osilodrostat)
    +
    quinidine (CYP2D6 inhibitor)
    1 interaction

    Monitor/Modify Tx

    osilodrostat + quinidine (CYP2D6 inhibitor)

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • quinine
  • Isturisa (osilodrostat)
    +
    quinine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + quinine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ramipril
  • Isturisa (osilodrostat)
    +
    ramipril
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ramipril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ramucirumab
  • Isturisa (osilodrostat)
    +
    ramucirumab
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ramucirumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • rasagiline
  • Isturisa (osilodrostat)
    +
    rasagiline
    1 interaction

    Monitor/Modify Tx

    osilodrostat + rasagiline

    adjust max rasagiline dose to 0.5 mg/day: combo may incr. rasagiline levels, risk of adverse effects (hepatic metabolism inhibited)

  • red yeast rice
  • Isturisa (osilodrostat)
    +
    red yeast rice
    1 interaction

    Monitor/Modify Tx

    osilodrostat + red yeast rice

    monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, red yeast rice contains varying amounts of lovastatin)

  • regorafenib
  • Isturisa (osilodrostat)
    +
    regorafenib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + regorafenib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • relacorilant
  • Isturisa (osilodrostat)
    +
    relacorilant
    1 interaction

    Monitor/Modify Tx

    osilodrostat + relacorilant

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • revumenib
  • Isturisa (osilodrostat)
    +
    revumenib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + revumenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ribociclib
  • Isturisa (osilodrostat)
    +
    ribociclib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ribociclib

    monitor ECG, electrolytes, CBC; decr. osilodrostat dose by 50%: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • rifabutin
  • Isturisa (osilodrostat)
    +
    rifabutin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + rifabutin

    monitor cortisol levels: combo may decr. osilodrostat levels, efficacy (hepatic metabolism induced)

  • rifampin
  • Isturisa (osilodrostat)
    +
    rifampin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + rifampin

    monitor cortisol levels: combo may decr. osilodrostat levels, efficacy (hepatic metabolism induced)

  • rimegepant
  • Isturisa (osilodrostat)
    +
    rimegepant
    1 interaction

    Monitor/Modify Tx

    osilodrostat + rimegepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ripretinib
  • Isturisa (osilodrostat)
    +
    ripretinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ripretinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ritonavir
  • Isturisa (osilodrostat)
    +
    ritonavir
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ritonavir

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • rizatriptan
  • Isturisa (osilodrostat)
    +
    rizatriptan
    1 interaction

    Monitor/Modify Tx

    osilodrostat + rizatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • romidepsin
  • Isturisa (osilodrostat)
    +
    romidepsin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + romidepsin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ropinirole
  • Isturisa (osilodrostat)
    +
    ropinirole
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ropinirole

    monitor BP; consider decr. ropinirole dose: combo may incr. ropinirole levels, risk of HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • rotigotine transdermal
  • Isturisa (osilodrostat)
    +
    rotigotine transdermal
    1 interaction

    Monitor/Modify Tx

    osilodrostat + rotigotine transdermal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • rucaparib
  • Isturisa (osilodrostat)
    +
    rucaparib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + rucaparib

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • sacituzumab govitecan
  • Isturisa (osilodrostat)
    +
    sacituzumab govitecan
    1 interaction

    Monitor/Modify Tx

    osilodrostat + sacituzumab govitecan

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • salmeterol inhaled
  • Isturisa (osilodrostat)
    +
    salmeterol inhaled
    1 interaction

    Monitor/Modify Tx

    osilodrostat + salmeterol inhaled

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • salsalate
  • Isturisa (osilodrostat)
    +
    salsalate
    1 interaction

    Monitor/Modify Tx

    osilodrostat + salsalate

    monitor BP w/ high-dose salsalate: combo may incr. risk of HTN (additive effects)

  • selinexor
  • Isturisa (osilodrostat)
    +
    selinexor
    1 interaction

    Monitor/Modify Tx

    osilodrostat + selinexor

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • selpercatinib
  • Isturisa (osilodrostat)
    +
    selpercatinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + selpercatinib

    monitor ECG, electrolytes, BP: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • sevoflurane
  • Isturisa (osilodrostat)
    +
    sevoflurane
    1 interaction

    Monitor/Modify Tx

    osilodrostat + sevoflurane

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • siponimod
  • Isturisa (osilodrostat)
    +
    siponimod
    1 interaction

    Monitor/Modify Tx

    osilodrostat + siponimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sirolimus
  • Isturisa (osilodrostat)
    +
    sirolimus
    1 interaction

    Monitor/Modify Tx

    osilodrostat + sirolimus

    monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited)

  • sirolimus albumin-bound
  • Isturisa (osilodrostat)
    +
    sirolimus albumin-bound
    1 interaction

    Monitor/Modify Tx

    osilodrostat + sirolimus albumin-bound

    decr. sirolimus albumin-bound dose to 56 mg/m2; monitor CBC, bleeding s/sx, potassium: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (including life-threatening), hypokalemia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • sodium benzoate
  • Isturisa (osilodrostat)
    +
    sodium benzoate
    1 interaction

    Monitor/Modify Tx

    osilodrostat + sodium benzoate

    monitor potassium, especially if hyperammonemia use: combo may incr. risk of hypokalemia (additive effects)

  • sodium phenylacetate
  • Isturisa (osilodrostat)
    +
    sodium phenylacetate
    1 interaction

    Monitor/Modify Tx

    osilodrostat + sodium phenylacetate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • sodium phenylbutyrate
  • Isturisa (osilodrostat)
    +
    sodium phenylbutyrate
    1 interaction

    Monitor/Modify Tx

    osilodrostat + sodium phenylbutyrate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • sodium polystyrene sulfonate
  • Isturisa (osilodrostat)
    +
    sodium polystyrene sulfonate
    1 interaction

    Monitor/Modify Tx

    osilodrostat + sodium polystyrene sulfonate

    monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • sodium thiosulfate
  • Isturisa (osilodrostat)
    +
    sodium thiosulfate
    1 interaction

    Monitor/Modify Tx

    osilodrostat + sodium thiosulfate

    if ototoxicity risk reduction use, monitor potassium; otherwise, caution advised: combo may incr. risk of hypokalemia (additive effects)

  • solriamfetol
  • Isturisa (osilodrostat)
    +
    solriamfetol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + solriamfetol

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • sorafenib
  • Isturisa (osilodrostat)
    +
    sorafenib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + sorafenib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • spironolactone
  • Isturisa (osilodrostat)
    +
    spironolactone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + spironolactone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • St. John's wort
  • Isturisa (osilodrostat)
    +
    St. John's wort
    1 interaction

    Monitor/Modify Tx

    osilodrostat + St. John's wort

    monitor cortisol levels: combo may decr. osilodrostat levels, efficacy (hepatic metabolism induced)

  • sufentanil
  • Isturisa (osilodrostat)
    +
    sufentanil
    1 interaction

    Monitor/Modify Tx

    osilodrostat + sufentanil

    monitor respiratory rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • sulfate bowel prep
  • Isturisa (osilodrostat)
    +
    sulfate bowel prep
    1 interaction

    Monitor/Modify Tx

    osilodrostat + sulfate bowel prep

    monitor potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • sulindac
  • Isturisa (osilodrostat)
    +
    sulindac
    1 interaction

    Monitor/Modify Tx

    osilodrostat + sulindac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sumatriptan
  • Isturisa (osilodrostat)
    +
    sumatriptan
    1 interaction

    Monitor/Modify Tx

    osilodrostat + sumatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sunitinib
  • Isturisa (osilodrostat)
    +
    sunitinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + sunitinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • tacrolimus
  • Isturisa (osilodrostat)
    +
    tacrolimus
    1 interaction

    Monitor/Modify Tx

    osilodrostat + tacrolimus

    monitor tacrolimus levels, ECG, renal fxn, BP: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • tadalafil
  • Isturisa (osilodrostat)
    +
    tadalafil
    1 interaction

    Monitor/Modify Tx

    osilodrostat + tadalafil

    monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

  • tafasitamab
  • Isturisa (osilodrostat)
    +
    tafasitamab
    1 interaction

    Monitor/Modify Tx

    osilodrostat + tafasitamab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • tagraxofusp
  • Isturisa (osilodrostat)
    +
    tagraxofusp
    1 interaction

    Monitor/Modify Tx

    osilodrostat + tagraxofusp

    monitor BP: combo may incr. risk of HTN (additive effects)

  • taletrectinib
  • Isturisa (osilodrostat)
    +
    taletrectinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + taletrectinib

    monitor ECG, electrolytes: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • telavancin
  • Isturisa (osilodrostat)
    +
    telavancin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + telavancin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • telmisartan
  • Isturisa (osilodrostat)
    +
    telmisartan
    1 interaction

    Monitor/Modify Tx

    osilodrostat + telmisartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • temsirolimus
  • Isturisa (osilodrostat)
    +
    temsirolimus
    1 interaction

    Monitor/Modify Tx

    osilodrostat + temsirolimus

    monitor CBC: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • terazosin
  • Isturisa (osilodrostat)
    +
    terazosin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + terazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • terbutaline
  • Isturisa (osilodrostat)
    +
    terbutaline
    1 interaction

    Monitor/Modify Tx

    osilodrostat + terbutaline

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • teriflunomide
  • Isturisa (osilodrostat)
    +
    teriflunomide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + teriflunomide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • testosterone
  • Isturisa (osilodrostat)
    +
    testosterone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + testosterone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • tetrabenazine
  • Isturisa (osilodrostat)
    +
    tetrabenazine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + tetrabenazine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • theophylline
  • Isturisa (osilodrostat)
    +
    theophylline
    1 interaction

    Monitor/Modify Tx

    osilodrostat + theophylline

    monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metabolism inhibited)

  • timolol
  • Isturisa (osilodrostat)
    +
    timolol
    1 interaction

    Monitor/Modify Tx

    osilodrostat + timolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • tipranavir
  • Isturisa (osilodrostat)
    +
    tipranavir
    1 interaction

    Monitor/Modify Tx

    osilodrostat + tipranavir

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • tivozanib
  • Isturisa (osilodrostat)
    +
    tivozanib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + tivozanib

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • tolmetin
  • Isturisa (osilodrostat)
    +
    tolmetin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + tolmetin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • tolvaptan
  • Isturisa (osilodrostat)
    +
    tolvaptan
    1 interaction

    Monitor/Modify Tx

    osilodrostat + tolvaptan

    consider decr. tolvaptan dose: combo may incr. tolvaptan levels, risk of adverse effects (hepatic metabolism inhibited)

  • topiramate
  • Isturisa (osilodrostat)
    +
    topiramate
    1 interaction

    Monitor/Modify Tx

    osilodrostat + topiramate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • torsemide
  • Isturisa (osilodrostat)
    +
    torsemide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + torsemide

    monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • trametinib
  • Isturisa (osilodrostat)
    +
    trametinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + trametinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • trandolapril
  • Isturisa (osilodrostat)
    +
    trandolapril
    1 interaction

    Monitor/Modify Tx

    osilodrostat + trandolapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • triamcinolone
  • Isturisa (osilodrostat)
    +
    triamcinolone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + triamcinolone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • triamterene
  • Isturisa (osilodrostat)
    +
    triamterene
    1 interaction

    Monitor/Modify Tx

    osilodrostat + triamterene

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • triazolam
  • Isturisa (osilodrostat)
    +
    triazolam
    1 interaction

    Monitor/Modify Tx

    osilodrostat + triazolam

    monitor respiratory rate; consider decr. triazolam dose: combo may incr. triazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • triclabendazole
  • Isturisa (osilodrostat)
    +
    triclabendazole
    1 interaction

    Monitor/Modify Tx

    osilodrostat + triclabendazole

    monitor ECG: combo may incr. triclabendazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • trifluridine
  • Isturisa (osilodrostat)
    +
    trifluridine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + trifluridine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • trimipramine
  • Isturisa (osilodrostat)
    +
    trimipramine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + trimipramine

    monitor BP: combo may incr. trimipramine levels, risk of HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • triptorelin
  • Isturisa (osilodrostat)
    +
    triptorelin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + triptorelin

    PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • tucatinib
  • Isturisa (osilodrostat)
    +
    tucatinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + tucatinib

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • ubrogepant
  • Isturisa (osilodrostat)
    +
    ubrogepant
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ubrogepant

    monitor BP; limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • vadadustat
  • Isturisa (osilodrostat)
    +
    vadadustat
    1 interaction

    Monitor/Modify Tx

    osilodrostat + vadadustat

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • valsartan
  • Isturisa (osilodrostat)
    +
    valsartan
    1 interaction

    Monitor/Modify Tx

    osilodrostat + valsartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • vamorolone
  • Isturisa (osilodrostat)
    +
    vamorolone
    1 interaction

    Monitor/Modify Tx

    osilodrostat + vamorolone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • vardenafil
  • Isturisa (osilodrostat)
    +
    vardenafil
    1 interaction

    Monitor/Modify Tx

    osilodrostat + vardenafil

    monitor ECG: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

  • vasopressin
  • Isturisa (osilodrostat)
    +
    vasopressin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + vasopressin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • vemurafenib
  • Isturisa (osilodrostat)
    +
    vemurafenib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + vemurafenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • venetoclax
  • Isturisa (osilodrostat)
    +
    venetoclax
    1 interaction

    Monitor/Modify Tx

    osilodrostat + venetoclax

    monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

  • venlafaxine
  • Isturisa (osilodrostat)
    +
    venlafaxine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + venlafaxine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • vepdegestrant
  • Isturisa (osilodrostat)
    +
    vepdegestrant
    1 interaction

    Monitor/Modify Tx

    osilodrostat + vepdegestrant

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • verapamil
  • Isturisa (osilodrostat)
    +
    verapamil
    1 interaction

    Monitor/Modify Tx

    osilodrostat + verapamil

    monitor BP: combo may incr. verapamil levels, risk of hypotension, bradycardia, AV block, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • vilanterol inhaled
  • Isturisa (osilodrostat)
    +
    vilanterol inhaled
    1 interaction

    Monitor/Modify Tx

    osilodrostat + vilanterol inhaled

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • viloxazine
  • Isturisa (osilodrostat)
    +
    viloxazine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + viloxazine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • vinblastine
  • Isturisa (osilodrostat)
    +
    vinblastine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + vinblastine

    monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

  • vincristine
  • Isturisa (osilodrostat)
    +
    vincristine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + vincristine

    monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

  • vinorelbine
  • Isturisa (osilodrostat)
    +
    vinorelbine
    1 interaction

    Monitor/Modify Tx

    osilodrostat + vinorelbine

    monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

  • voclosporin
  • Isturisa (osilodrostat)
    +
    voclosporin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + voclosporin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • voriconazole
  • Isturisa (osilodrostat)
    +
    voriconazole
    1 interaction

    Monitor/Modify Tx

    osilodrostat + voriconazole

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • warfarin
  • Isturisa (osilodrostat)
    +
    warfarin
    1 interaction

    Monitor/Modify Tx

    osilodrostat + warfarin

    monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

  • yohimbe
  • Isturisa (osilodrostat)
    +
    yohimbe
    1 interaction

    Monitor/Modify Tx

    osilodrostat + yohimbe

    monitor BP: combo may incr. risk of HTN (additive effects)

  • zanubrutinib
  • Isturisa (osilodrostat)
    +
    zanubrutinib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + zanubrutinib

    monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • zavegepant
  • Isturisa (osilodrostat)
    +
    zavegepant
    1 interaction

    Monitor/Modify Tx

    osilodrostat + zavegepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ziftomenib
  • Isturisa (osilodrostat)
    +
    ziftomenib
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ziftomenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ziv-aflibercept
  • Isturisa (osilodrostat)
    +
    ziv-aflibercept
    1 interaction

    Monitor/Modify Tx

    osilodrostat + ziv-aflibercept

    monitor BP: combo may incr. risk of HTN (additive effects)

  • zolmitriptan
  • Isturisa (osilodrostat)
    +
    zolmitriptan
    1 interaction

    Monitor/Modify Tx

    osilodrostat + zolmitriptan

    monitor BP: combo may incr. zolmitriptan levels, risk of HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • zonisamide
  • Isturisa (osilodrostat)
    +
    zonisamide
    1 interaction

    Monitor/Modify Tx

    osilodrostat + zonisamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

Caution Advised

  • abrocitinib
  • Isturisa (osilodrostat)
    +
    abrocitinib
    1 interaction

    Caution Advised

    osilodrostat + abrocitinib

    caution advised: combo may incr. abrocitinib and active metabolite levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited)

  • cariprazine
  • Isturisa (osilodrostat)
    +
    cariprazine
    1 interaction

    Caution Advised

    osilodrostat + cariprazine

    caution advised: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

  • carisoprodol
  • Isturisa (osilodrostat)
    +
    carisoprodol
    1 interaction

    Caution Advised

    osilodrostat + carisoprodol

    caution advised: combo may incr. carisoprodol levels, decr. active metabolite meprobamate levels, alter risk of adverse effects and efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite)

  • clopidogrel
  • Isturisa (osilodrostat)
    +
    clopidogrel
    1 interaction

    Caution Advised

    osilodrostat + clopidogrel

    caution advised: combo may decr. clopidogrel active metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion of clopidogrel to active metabolite)

  • cobimetinib
  • Isturisa (osilodrostat)
    +
    cobimetinib
    1 interaction

    Caution Advised

    osilodrostat + cobimetinib

    caution advised: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • conivaptan
  • Isturisa (osilodrostat)
    +
    conivaptan
    1 interaction

    Caution Advised

    osilodrostat + conivaptan

    caution advised: combo may incr. conivaptan levels, risk of overly rapid serum sodium correction, neurologic sequelae, other adverse effects (hepatic metabolism inhibited)

  • cyclophosphamide
  • Isturisa (osilodrostat)
    +
    cyclophosphamide
    1 interaction

    Caution Advised

    osilodrostat + cyclophosphamide

    caution advised: combo may decr. cyclophosphamide active metabolite levels, efficacy (hepatic metabolism possibly inhibited, decr. conversion to active metabolite)

  • daridorexant
  • Isturisa (osilodrostat)
    +
    daridorexant
    1 interaction

    Caution Advised

    osilodrostat + daridorexant

    caution advised: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • duloxetine
  • Isturisa (osilodrostat)
    +
    duloxetine
    1 interaction

    Caution Advised

    osilodrostat + duloxetine

    caution advised: combo may incr. duloxetine levels, risk of adverse effects (hepatic metabolism inhibited)

  • elinzanetant
  • Isturisa (osilodrostat)
    +
    elinzanetant
    1 interaction

    Caution Advised

    osilodrostat + elinzanetant

    caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • melatonin
  • Isturisa (osilodrostat)
    +
    melatonin
    1 interaction

    Caution Advised

    osilodrostat + melatonin

    caution advised: combo may incr. melatonin levels, risk of adverse effects (hepatic metabolism inhibited)

  • palovarotene
  • Isturisa (osilodrostat)
    +
    palovarotene
    1 interaction

    Caution Advised

    osilodrostat + palovarotene

    caution advised: combo may incr. palovarotene levels, risk of adverse effects (hepatic metabolism inhibited)

  • perphenazine
  • Isturisa (osilodrostat)
    +
    perphenazine
    1 interaction

    Caution Advised

    osilodrostat + perphenazine

    caution advised: combo may incr. perphenazine levels, risk of adverse effects (hepatic metabolism inhibited)

  • proguanil
  • Isturisa (osilodrostat)
    +
    proguanil
    1 interaction

    Caution Advised

    osilodrostat + proguanil

    caution advised: combo may incr. proguanil levels, risk of adverse effects; may decr. proguanil active metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite)

  • ramelteon
  • Isturisa (osilodrostat)
    +
    ramelteon
    1 interaction

    Caution Advised

    osilodrostat + ramelteon

    caution advised: combo may incr. ramelteon levels, risk of adverse effects (hepatic metabolism inhibited)

  • repotrectinib
  • Isturisa (osilodrostat)
    +
    repotrectinib
    1 interaction

    Caution Advised

    osilodrostat + repotrectinib

    caution advised: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • riluzole
  • Isturisa (osilodrostat)
    +
    riluzole
    1 interaction

    Caution Advised

    osilodrostat + riluzole

    caution advised: combo may incr. riluzole levels, risk of adverse effects (hepatic metabolism inhibited)

  • rilzabrutinib
  • Isturisa (osilodrostat)
    +
    rilzabrutinib
    1 interaction

    Caution Advised

    osilodrostat + rilzabrutinib

    caution advised: combo may incr. rilzabrutinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • roflumilast
  • Isturisa (osilodrostat)
    +
    roflumilast
    1 interaction

    Caution Advised

    osilodrostat + roflumilast

    caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

  • roflumilast topical
  • Isturisa (osilodrostat)
    +
    roflumilast topical
    1 interaction

    Caution Advised

    osilodrostat + roflumilast topical

    caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

  • sirolimus topical
  • Isturisa (osilodrostat)
    +
    sirolimus topical
    1 interaction

    Caution Advised

    osilodrostat + sirolimus topical

    caution advised: combo may incr. sirolimus levels, risk of adverse effects (hepatic metabolism inhibited)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@272f53ba
  • hypocortisolism
  • adrenal insufficiency
  • QT prolongation
  • neutropenia

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@6b7560d6
  • adrenal insufficiency
  • fatigue
  • appetite decr.
  • nausea
  • arthralgia
  • hypocortisolism
  • headache
  • myalgia
  • edema
  • diarrhea
  • nasopharyngitis
  • vomiting
  • dizziness
  • hypokalemia
  • back pain
  • rash
  • hypotension
  • tachycardia
  • HTN
  • corticotropin incr.
  • abdominal pain
  • QT prolongation
  • UTI
  • pruritus
  • testosterone incr.
  • fever
  • anemia
  • cough
  • influenza
  • viral infection
  • hirsutism
  • acne
  • dyspepsia
  • insomnia
  • anxiety
  • depression
  • gastroenteritis
  • malaise
  • neutropenia
  • alopecia
  • ALT or AST incr.

Safety/Monitoring .

Monitoring Parameters
K, Mg at baseline; ECG at baseline, within 1wk of tx start, then as clinically indicated or more frequently if QT prolongation risk; adrenal function if hepatic impairment

Pregnancy/Lactation .

Pregnancy

Clinical Summary

weigh risk/benefit during pregnancy; no human data available; no known risk of teratogenicity based on animal data at doses up to 8x MRHD

Lactation

Clinical Summary

avoid breastfeeding during tx and x1wk after D/C; no human data available, though theoretical risk of infant adrenal insufficiency based on drug's mechanism of action; no human data available to assess effects on milk production

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@220c051e

Metabolism: for osilodrostat: liver; CYP450: 2B6, 2D6, 3A4 substrate; UGT: substrate (enzymes not defined)

Excretion: for osilodrostat: urine 90.6% (5.2% unchanged), feces 1.6%; Half-life: 4h

Subclass: Cushing Syndrome

Mechanism of Action
for osilodrostat: inhibits 11 beta-hydroxylase (CYP11B1), blocking cortisol biosynthesis

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: Recordati Rare Diseases Inc.

com.epocrates.rxweb.beans.DrugOtherInfoBean@7f00141a

DEA/FDA: Rx

Retail Price

Estimated prices only. For current pricing, visit GoodRx.

oral tablet:

  • 1 mg (1 carton, 20 tablets): $2,578.00
  • 5 mg (1 carton, 20 tablets): $8,835.00
  • 10 mg (1 carton, 20 tablets): $10,489.00

oral tablet:

  • 1 mg (1 carton, 3 blister packs of 20 tablets): $7,714.00
  • 5 mg (1 carton, 3 blister packs of 20 tablets): $26,485.00
  • 10 mg (1 carton, 3 blister packs of 20 tablets): $31,449.00

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback Cookie Preferences
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information